Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients

Joy, Parijat S.; Guddati, Achuta Kumar; Shapira, Iuliana

doi:10.1007/s00432-018-2661-1

Cited by 32 publications

(26 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients receiving multi-modality treatment for their cancer with surgery, radiation and chemotherapy are at an increased risk for developing TCM. When this condition occurs in a patient with malignancy, it is associated with worse outcomes compared to the general population [84]. Therefore, it is essential for medical professionals to recognize, monitor, and treat this condition appropriately.…”

Section: Resultsmentioning

confidence: 99%

“…Patients with malignancy not only have an increased risk for TCM development, they experience worse outcomes compared to patients with TCM in the absence of malignancy. Based on National Inpatient Sample (NIS) analysis study [84], TCM with coexisting malignancy had a significantly higher mortality (13.8 vs. 2.9%, p < 0.0001), length of stay (7 vs. 4 days, p < 0.0001) and total charges ($29,291 vs. $36,231, p < 0.0001), compared to those with no malignancy. Thus, early recognition and prompt initiation of appropriate treatment may help lower mortality and reduce health care costs in these patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Takotsubo cardiomyopathy in cancer patients

et al. 2019

View full text Add to dashboard Cite

Background: Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM). Main body: Takotsubo cardiomyopathy, also known as stress cardiomyopathy, is a clinical syndrome that generally presents as chest pain mimicking acute coronary syndrome or as an acute heart failure characterized by severe left ventricular systolic dysfunction in response to emotional, physical, or medical stress. The potential triggers for Takotsubo syndrome in cancer patients include the emotional turmoil of a cancer diagnosis, the inflammatory state of the cancer itself, and the physical stress of cancer surgery, systemic anti-neoplastic therapy, and radiation treatment. TCM is becoming increasingly recognized among patients with cancer and has been associated with adverse outcomes in this patient population. In this study, we searched the Pubmed database using keywords "Takotsubo cardiomyopathy", "cancer", and "anti-neoplastic therapy" to review case reports of Takotsubo syndrome occurring in oncologic patients after systemic anti-neoplastic therapy. Clinical presentation, electrocardiogram, laboratory data, transthoracic echocardiogram and coronary angiogram results, and patient outcomes were collected and analyzed. Conclusion: Patients with cancer are at an elevated risk for developing stress cardiomyopathy, and it is important to know which cancer drugs have been associated with the development of the Takotsubo syndrome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Takotsubo cardiomyopathy in cancer patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our study demonstrated that malignancy was associated with~70% increase in inhospital mortality risk during index hospitalization and~60% increase in overall 30-day mortality risk in patients with TTS. A previous study from National Inpatient Sample 2007 to 2013 showed that solid cancer was associated with 3.4 times increase in in-hospital mortality among TTS patients [37]. Our analysis included all types of cancer (solid or hematologic cancer), which may explain slightly lower in-hospital mortality.…”

Section: Discussionmentioning

confidence: 96%

Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis

Jang

Yeo

Jonas

et al. 2021

JCM

View full text Add to dashboard Cite

The association between malignancy and readmission after Takotsubo syndrome (TTS) hospitalization has not been fully described. We sought to examine the rates, cause, and cost of 30-day readmissions of TTS, with or without malignancy, by utilizing Nationwide Readmissions Databases from 2010 to 2014. We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy tended to be older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio (OR), 1.35; 95% confidence interval (CI), 1.18–1.56). Non-cardiac causes were the most common causes of readmission for TTS patients with malignancy versus without malignancy (75.5% vs. 68.1%, p < 0.001). The 30-day readmission rate due to recurrent TTS was very low in both groups (0.4% and 0.5%; p = 0.47). The total costs were higher by 25% (p < 0.001) in TTS patients with vs. without malignancy. In summary, among patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission and increased costs. These findings highlight the importance of optimized management for TTS patients with malignancy.

show abstract

“…Our study demonstrated that malignancy was associated with ~70% increase in in-hospital mortality risk during index hospitalization and ~60% increase in overall 30-day mortality risk in patients with TTS. A previous study from National Inpatient Sample 2007 to 2013 showed that solid cancer was associated with 3.4 times increase in in-hospital mortality among TTS patients [37]. Our analysis included all types of cancer (solid or hematologic cancer), which may explain slightly lower in-hospital mortality.…”

Section: Discussionmentioning

confidence: 96%

Thirty-Day Readmission Rates After Takotsubo Syndrome With or Without Malignancy: A Nationwide Readmissions Database Analysis

Jang

Yeo

Jonas

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Association of malignancy with readmission after TTS hospitalization has not been fully described. We sought to examine the rates, cause and cost of 30-day readmissions and 30-day all-cause mortality of Takotsubo syndrome (TTS) patients with or without malignancy. Methods: The Nationwide Readmissions Databases from 2010 to 2014 were queried to identify and compare baseline characteristics and outcomes of patients hospitalized for TTS with and without malignancy. Results: We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy were older (70.6 ± 0.2 vs. 66.1 ± 0.1, p < 0.001), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio [OR], 1.35; 95% confidence interval [CI], 1.18 - 1.56). Majority (75.5%) of the etiologies for readmissions were non-cardiac, with infection being most common (20.1%). The 30-day readmission rate due to the recurrent TTS was similar in both groups (0.4% and 0.5%, respectively; p = 0.47). Importantly, 30-day all-cause mortality was higher in TTS with vs. without malignancy (4.8% vs 2.5%; OR, 1.62; 95% CI, 1.25 - 2.10). The total costs (index admission + readmission) were higher by 25% (p < 0.001) in TTS patients with malignancy vs. without malignancy. Conclusions: In patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission, mostly attributable to non-cardiac etiologies. Importantly, the 30-day all-cause mortality and cost were also significantly higher. These findings highlight the importance of optimization of treatment and follow up in patients with malignancy after hospitalizations for TTS.

show abstract

Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients

Cited by 32 publications

References 33 publications

Takotsubo cardiomyopathy in cancer patients

Takotsubo cardiomyopathy in cancer patients

Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis

Thirty-Day Readmission Rates After Takotsubo Syndrome With or Without Malignancy: A Nationwide Readmissions Database Analysis

Contact Info

Product

Resources

About